A pivotal clinical development has sent Zenas BioPharma (NASDAQ: ZBIO) shares climbing higher, reshaping the company’s ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...

Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

TG Therapeutics (($TGTX)) announced an update on their ongoing clinical study. The clinical study titled ‘Ublituximab in Pediatric Participants ...

ASX 200 futures are down 39pts (-0.43%) as of 8:30 am AEDT. Here's what you need to know before the market opens.

Unlike hydrogen or electricity, e-fuels are drop-in replacements compatible with existing internal combustion engines, pipelines and refineries. Their production, however, is chemically and ...

Zenas BioPharma shares jumped in premarket trading after the company reported highly positive trial data for its multiple-sclerosis treatment. Shares traded over 59% higher ahead of the morning bell ...

Investing.com -- Zenas BioPharma (NASDAQ:ZBIO) stock surged 80% on Monday after the company announced positive results from its Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

Unicorn featured an awesome battle which called out the Zeon Remnants to fight. This led to a skirmish which included a ...